These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 16899107)

  • 1. Interleukin-6 and chronic inflammation.
    Gabay C
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S3. PubMed ID: 16899107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
    Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
    J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin.
    Marin V; Montero-Julian FA; Grès S; Boulay V; Bongrand P; Farnarier C; Kaplanski G
    J Immunol; 2001 Sep; 167(6):3435-42. PubMed ID: 11544336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.
    Dayer JM; Choy E
    Rheumatology (Oxford); 2010 Jan; 49(1):15-24. PubMed ID: 19854855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
    Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.
    Le TT; Karmouty-Quintana H; Melicoff E; Le TT; Weng T; Chen NY; Pedroza M; Zhou Y; Davies J; Philip K; Molina J; Luo F; George AT; Garcia-Morales LJ; Bunge RR; Bruckner BA; Loebe M; Seethamraju H; Agarwal SK; Blackburn MR
    J Immunol; 2014 Oct; 193(7):3755-68. PubMed ID: 25172494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD14 is an acute-phase protein.
    Bas S; Gauthier BR; Spenato U; Stingelin S; Gabay C
    J Immunol; 2004 Apr; 172(7):4470-9. PubMed ID: 15034063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
    Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
    Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6: Biology, signaling and strategies of blockade.
    Schaper F; Rose-John S
    Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of IL-6/sIL-6R complex and its natural inhibitor sgp130 in modulation of inflammatory process].
    Augustyniak D; Majkowska-Skrobek G; Basiewicz-Worsztynowicz B; Jankowski A
    Postepy Biochem; 2006; 52(2):194-203. PubMed ID: 17078509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.
    Dominitzki S; Fantini MC; Neufert C; Nikolaev A; Galle PR; Scheller J; Monteleone G; Rose-John S; Neurath MF; Becker C
    J Immunol; 2007 Aug; 179(4):2041-5. PubMed ID: 17675459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1R signalling contributes to IL-6 production and T cell dependent inflammation in rheumatoid arthritis.
    Erlandsson MC; Töyrä Silfverswärd S; Nadali M; Turkkila M; Svensson MND; Jonsson IM; Andersson KME; Bokarewa MI
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2158-2170. PubMed ID: 28583713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.